logo
logo

Gt Biopharma Announces $16 Million In Warrant Exercise Proceeds

Jul 28, 2021•about 4 years ago

Amount Raised

$16 Million

Beverly Hills

Description

GT Biopharma, Inc. (NASDAQ: GTBP), an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKETM) technology platform is pleased to announce the company has raised over $16 million in proceeds from the exercise of warrants. The warrants were issued as part of the $27 million financing that closed in February 2021.

Company Information

Company

Gt Biopharma

Location

Beverly Hills, California, United States

About

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKETM NK cell engager platform. Our TriKETM platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKETM technology. For more information, please visit www.gtbiopharma.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech